Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 17/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808068 | 0.86 | HIF1A (0.48) | HIF1AEPAS1PTGS1PTGS2XDH | |
| SCHEMBL30523641 | 0.83 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL507142 | 0.83 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL9032911 | 0.79 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL5868243 | 0.79 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL9032078 | 0.77 | HIF1A (0.53) | HIF1AEPAS1 | |
| Eulatachromene SCHEMBL9033640 | 0.77 | HIF1A (0.53) | HIF1AEPAS1PTGS1PTGS2XDH | |
| SCHEMBL14930294 | 0.75 | HIF1A (0.64) | HIF1AEPAS1 | |
| SCHEMBL14930293 | 0.75 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL14541294 | 0.74 | HIF1A (0.56) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168161-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026047-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168161-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NAT10 | HIF1A 3098/4885EPAS1 4052/4885PTGS1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.